Management of patients with metastatic breast cancer

Advances in Therapy

Volumn 28, Issue SUPPL. 6, 2011, Pages 50-65

  Jurado, J Cruz ^a   Aznar, P Richart ^b   Mata, J García ^c   Martínez, R Fernández ^d   Fernández, I Peláez ^d   Gimeno, T Sampedro ^d   Calvo, E Galve ^e   Jaso, L Murillo ^f   Marqués, E Polo ^g   Palomo, A García ^h  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b HOSPITAL DE MANISES   (Spain)

^c Oncology Department   (Spain)

^d HOSPITAL DE CABUEÑES   (Spain)

^e HOSPITAL DE BASURTO   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g Hospital Ernest Lluch De Calatayud   (Spain)

^h HOSPITAL DE LEÓN   (Spain)

Author keywords

Anastrozole; Breast cancer; Exemestane; Fulvestrant; Letrozole; Targeted therapies

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; BEVACIZUMAB; BUSERELIN; CEDIRANIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPOTHILONE B; EVEROLIMUS; EXEMESTANE; FORMESTANE; FULVESTRANT; GEFITINIB; GONADORELIN AGONIST; GOSERELIN; HORMONE RECEPTOR; HYDROCORTISONE; LAPATINIB; LETROZOLE; LEUPRORELIN; MEGESTROL ACETATE; PERTUZUMAB; TAMOXIFEN; TAMOXIFEN CITRATE; TEMSIROLIMUS; TOREMIFENE; TRASTUZUMAB; TRIPTORELIN; UNINDEXED DRUG; VOROZOLE;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CROSS RESISTANCE; DISEASE FREE INTERVAL; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HOT FLUSH; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS POTENTIAL; MUSCULOSKELETAL DISEASE; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; SURVIVAL TIME; THROMBOEMBOLISM; TUMOR FLARE; VAGINA BLEEDING;

ADULT; AGE FACTORS; AGED; ANDROSTADIENES; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE MANAGEMENT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NITRILES; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 82455166815     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-011-0046-9     Document Type: Article

References (70)

1. Livestrong™: What is metastatic breast cancer? Available at http://www.livestrong.com/ article/153776-what-is-metastatic-breast-cancer/ Accessed July 12, 2011.
2. National Comprehensive Cancer Network Website. Your breast cancer survival guide. Available at http://www.nccn.org/about/ publications/pdf/Your- Breast-Cancer- SURVIVAL-Guide.pdf Accessed July 12, 2011.
3. Burstein HJ, Prestrud AA, Seidenfeld J. American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010;28:3784-3796.
4. Jones S, Vogel C, Arkhipov A, et al. Aromasin Study Group. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. J Clin Oncol. 1999;17:3418-3425. (Pubitemid 29517909)
5. Thürlimann B, Paridaens R, Serin D, et al. Exemestane Study Group. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: A phase II multicentre multinational study. Eur J Cancer. 1997;33:1767-1773. (Pubitemid 28129201)
6. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase iii randomized double-blind trial. J Clin Oncol. 2000;18:1399-1411. (Pubitemid 30205385)
7. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as firstline hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol. 2003;14:1391-1398. (Pubitemid 37185285)
8. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008;26:4883-4890.
9. Chernozemsky I, Kalinov K, Tzekov H, et al. Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13-16, 2007; San Antonio, TX.
10. Glück S. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer. Am J Clin Oncol. 2010;33:314-319.
11. Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology. 2005;69:471-477.
12. Chia S, Gradishar W, Mauriac L, et al. Double- blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptorpositive, advanced breast cancer: Results from EFECT. J Clin Oncol. 2008;26:1664-1670.
13. Riemsma R, Forbes CA, Kessels A, et al. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer. Breast Cancer Res Treat. 2010;123:9-24.
14. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. National Comprehensive Cancer Network Website. http://www.nccn. org/professionals/ physician-gls/pdf/breast.pdf. Accessed June 28, 2011.
15. Brueggemeier, Hackett JC, Diaz-Cruz ES. Aromatase Inhibitors in the Treatment of Breast Cancer. Endoc Rev. 2005;26:331-345. (Pubitemid 40686647)
16. Geisler J. Aromatase inhibitors: From bench to bedside and back. Breast Cancer. 2008;15:17-26.
17. Geisler J, Haynes B, Anker G, Dowsett H, Lønning PE. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20:751-757. (Pubitemid 34111382)
18. Rose C, Vtoraya O, Pluzanska A, et al. An open randomized trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer. 2003;39:2318-2327. (Pubitemid 37214856)
19. Sainsbury R. Aromatase inhibition in the treatment of advanced breast cancer: Is there a relationship between potency and clinical efficacy? Br J Cancer. 2004;90:1733-1739. (Pubitemid 38725643)
20. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann Oncol. 1998;9:639-645. (Pubitemid 28318197)
21. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol. 1998;16:453-461. (Pubitemid 28135586)
22. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101-2109. (Pubitemid 46606358)
23. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer. 1998;83:1142-1152. (Pubitemid 28419067)
24. Bonneterre J, Thürlimann B, Robertson JFR, et al. Arimidex Study Group. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000;18:3748-3757.
25. Nabholtz JM, Buzdar A, Pollak M, et al. Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. J Clin Oncol. 2000;18:3758-3767.
26. Bonneterre J, Buzdar A, Nabholtz JM, et al. Arimidex Writing Committee. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247-2258.
27. Croxtall JD, McKeage K. Fulvestrant: A review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs. 2011;71:363-80.
28. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995;345:29-30.
29. Perey L, Paridaens R, Nolé F, et al. Fulvestrant (Faslodex™) as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors: Update of a phase II SAKK trial. Breast Cancer Res Treat. 2004;88(Suppl. 1):S236. Abstract 6048.
30. Ingle JN, Rowland KM, Suman VJ, et al. Evaluation of fulvestrant in women with advanced breast cancer and progression on prior aromatase inhibitor therapy: A phase II trial of the North Central Cancer Treatment Group. Breast Cancer Res Treat. 2004;88(Suppl. 1):S38. Abstract 409.
31. Osborne CK, Pippen J, Jones SE, et al. Doubleblind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol. 2002;20:3386-3395.
32. Howell A, Robertson JFR, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;16:3396-3403.
33. Robertson JFR, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials. Cancer. 2003;98:229-238. (Pubitemid 36828445)
34. Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: A prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005;104:236-239. (Pubitemid 40993248)
35. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605-1613. (Pubitemid 41079798)
36. DocGuide. High-dose fulvestrant reduces tumor cell growth. Presented at the 30th Annual San Antonio Breast Cancer Symposium. Available at http://www. docguide.com/high-dose-fulvestrant-reduces-tumorcell- growth-presented-sabcs Accessed July 12, 2011.
37. Kuter I, Hegg R, Singer CF, Badwe R, Lowe E. NEWEST Investigators. Fulvestrant 500 mg vs 250 mg: First results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptorpositive breast cancer. Breast Cancer Res Treat. 2007;106(Suppl. 1):S7. Abstract 23.
38. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM Phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor- positive advanced breast cancer. J Clin Oncol. 2010;28:4594-4600.
39. Robertson JFR, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: Results from the FIRST study. J Clin Oncol. 2009;27:4530-4535.
40. Rose C, Mouridsen HT. Endocrine therapy of advanced breast cancer. Acta Oncol. 1988;27:721-728. (Pubitemid 19051897)
41. Puhalla S, Brufsky A, Davidson N. Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast. 2009;18:S122-130.
42. Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R. Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol. 2001;19:343-353. (Pubitemid 32112845)
43. Klijn JGM, Beex LVAM, Mauriac L, et al. European Organization for Research and Treatment of Cancer- Breast Cancer Cooperative Group. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst. 2000;92:903-911. (Pubitemid 30429190)
44. Cheung KL, Agrawal A, Folkerd E, Dowsett M, Robertson JFR, Winterbottom L. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women. Eur J Cancer. 2010;46:2936-2942.
45. Carlson RW, Theriault R, Schurman CM, et al. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women. J Clin Oncol. 2010;28:3917-3921.
46. Roche HH, Thierry D, Chieze S, et al. Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial. J Clin Oncol. 2009;27:15S. Abstract 1079
47. Robertson JFR, Semiglazov V, Nemsadze G, et al. Study 41 Investigators. Effects of fulvestrant 250 mg in premenopausal women with oestrogen receptor-positive primary breast cancer. Eur J Cancer. 2007;43:64-70. (Pubitemid 46054466)
48. Young OE, Renshaw L, Macaskill EJ, et al. Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer. 2008;44:391-399.
49. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011;12:631-641.
50. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262-1271. (Pubitemid 41535367)
51. Bossung V, Harbeck N. Angiogenesis inhibitors in the management of breast cancer. Curr Opin Obstet Gynecol. 2010;22:79-86.
52. Hong Y, Yu B, Sherman M, Yuan Y-C, Zhou D, Chen S. Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. Mol Endocrinol. 2007;21:401-414. (Pubitemid 46184893)
53. Miller WR, Bartlett J, Brodie AMH, et al. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist. 2008;13:829-837.
54. Murray R, Pitt P. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat. 1995;35:249-253.
55. Lønning PE, Paridaens R, Thürlimann B, Piscitelli G, di Salle E. Exemestane experience in breast cancer treatment. J Steroid Biochem Mol Biol. 1997;61:151-155. (Pubitemid 27455673)
56. Carlini P, Bria E, Giannarelli D, et al. New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: A pooled analysis of the randomized trials. Cancer. 2005;104:1335-1342. (Pubitemid 41356147)
57. Iaffaioli RV, Formato R, Tortoriello A, et al. Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer. Br J Cancer. 2005;92:1621-1625. (Pubitemid 40756471)
58. Lester J, Coleman R. The use of bisphosphonates in breast cancer. Menopause Int. 2005;11:12-17 (Pubitemid 40392765)
59. Jordan VC. The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol. 2008;26:3073-3082.
60. Schwartzberg LS, Franco SX, Florance A, O'Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptorpositive metastatic breast cancer. Oncologist. 2010;15:122-129.
61. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27:5538-5546.
62. Kaufman B, Mackey JR, Clemens MR. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM Study. J Clin Oncol. 2009;27:5529-5537.
63. Osborne CK, Neven P, Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: A randomized phase II study. Clin Cancer Res. 2011;17:1147-1159.
64. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27:2630-2637.
65. Chow LWC, Sun Y, Jassem J, et al. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat. 2006;100(Suppl. 1):S28. Abstract 6091.
66. Callahan R, Hurvitz S. Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol. 2011;23:37-43.
67. Fornier M. Ixabepilone plus capecitabine for breast cancer patients with an early metastatic relapse after adjuvant chemotherapy: Two clinical trials. Clin Breast Cancer. 2010;10:352-358.
68. O'Shaughnessy J, Osborne C, Pippen JE, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-214.
69. Bäuerle T, Komljenovic D, Merz M, et al. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int J Cancer. 2011;128:2453-2462.
70. Burstein HJ. Novel agents and future directions for refractory breast cancer. Semin Oncol. 2011;38:S17-24.